Caris Life Sciences to Present Research Supporting Clinical Utility of Caris Molecular Intelligence® at 2016 Genitourinary Cancers Symposium

News provided by

Jan 07, 2016, 07:00 ET

IRVING, Texas, Jan. 7, 2016 /PRNewswire/ -- Caris Life Sciences®,a leading biotechnology company focused on fulfilling the promise of precision medicine, announces today that it will present four poster presentations at the 2016 Genitourinary Cancers Symposium from January 7-9, 2016 in San Francisco, Calif.

Each of the four studies being presented utilizes Caris Molecular Intelligence®, the company's panomic comprehensive, multiplatform tumor profiling service, to facilitate biomarker identification and molecular characterization of genitourinary cancers. Using Caris Molecular Intelligence, investigators were able to identify potentially overlapping and/or alternative therapeutic options, including immunotherapies and targeted therapies, for patients with different subtypes of genitourinary cancers.

Following is a schedule of Caris Life Sciences poster presentations:

Date and Time: Thursday January 7, 11:30 a.m. – 1:00 p.m. and 5:15 p.m. – 6:45 p.m.
Title: Taxane sensitivity markers in prostate cancer
Abstract: 285
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session A; Board M12
Authors: Rebecca Feldman, Michael Castro, Sandeep Reddy, Charles Myers
Collaborators: Personalized Cancer Medicine PLLC, American Institute for Diseases of the Prostate

Date and Time: Thursday January 7, 11:30 a.m. – 1:00 p.m. and 5:15 p.m. – 6:45 p.m.
Title: Frequency of BRCA mutations and co-occurring alterations in prostate cancer
Abstract: 289
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session A; Board M16
Authors: Charles Myers, Rebecca Feldman, Brian Abbott, Sandeep Reddy, Michael Castro
Collaborators: American Institute for Diseases of the Prostate, Personalized Cancer Medicine PLLC

Date and Time: Friday January 8, 12:15 p.m. - 1:45 p.m. and 6:00 p.m. - 7:00 p.m.
Title: Molecular profiling of non-urothelial bladder cancer: adenocarcinoma and squamous cell carcinoma
Abstract: 423
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session B; Board H16
Authors: Daniel M. Geynisman, David Arguello, Sandeep Reddy, Zoran Gatalica
Collaborator: Fox Chase Cancer Center

Date and Time: Saturday January 9, 7:00 a.m. - 7:55 a.m. and 11:30 a.m. - 1:00 p.m.
Title: Comprehensive profiling of renal medullary and collecting duct carcinomas
Abstract: 572
Poster Display Location: Moscone Center, Level 1, West Hall
Session: Poster Session C; Board G11
Authors: Thai Huu Ho, Jeffrey Swensen, Anatole Ghazalpour, Ondrej Hes, Melissa L. Stanton, Monika Joshi, Souzan Sanati, Priyanka Purnanada, David Arguello, Sandeep Reddy, Zoran Gatalica
Collaborators: Mayo Clinic, University Hospital Plzen, Penn State Milton S. Hershey Medical Center, Washington University

About Caris Life Sciences®
Founded by David D. Halbert in 2008, Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's healthcare information and comprehensive tumor profiling service with more than 80,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient's tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

SOURCE Caris Life Sciences